Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Novara – page 140

2 684 clinical trials in Novara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Novara at a glance
2 684
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 684 trials in Novara

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Durvalumab and Chemo-Immunotherapy for Patients with Stage III Unresectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione IRCCS Policlinico San Matteo

Ovarian cancer

Not recruiting

Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Pancreatic carcinoma metastatic

Not recruiting

Study of RMC-6236 compared to standard therapy in previously treated metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Alemtuzumab
  • Sponsor:Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S

Asthma

Not recruiting

Study on the Safety and Effectiveness of AZD8630 for Adults with Uncontrolled Asthma at Risk of Exacerbations

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg1 Lambda Fab Fragment Against Thymic Stromal Lymphopoietin
  • Sponsor:Astrazeneca AB

Cushing's syndrome

Not recruiting

Study on the Long-Term Safety of Relacorilant for Patients with Cushing Syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Corcept Therapeutics Inc.

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Kaposi's sarcoma

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Classic Kaposi Sarcoma After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

Hormone-refractory prostate cancer+1

Not recruiting

Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib with Rituximab-CHOP for Untreated Patients with Diffuse Large B-cell Lymphoma at High Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Italiana Linfomi Ets

Follicular lymphoma

Not recruiting

Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Fondazione Italiana Linfomi Ets

Plasma cell myeloma refractory

Not recruiting

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Kite Pharma Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Novara

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on hematologic malignancies and solid tumors, investigating innovative treatments for various cancer types including leukemia, breast cancer, and lung cancer.

  • Advanced breast cancer therapies
  • Chronic myeloid leukemia treatments
  • Non-small cell lung cancer interventions

Studies evaluating combination therapies and targeted treatments to improve patient outcomes.

02 Cardiovascular Studies

Research focusing on heart failure prevention and treatment strategies, particularly exploring new drug combinations and their impact on cardiovascular outcomes.

  • Heart failure risk reduction
  • Cardiovascular death prevention
  • Chronic kidney disease management

Innovative approaches combining multiple therapeutic agents to address cardiovascular risks.

03 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Sjögren's Syndrome and rheumatoid arthritis, with emphasis on novel therapeutic approaches.

  • Biomarker-guided treatments
  • Long-term safety evaluations
  • Innovative therapeutic combinations

Focus on developing targeted therapies for better disease management and patient care.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.